Trendlines teams up with Ozi Amanat as Startup SG Equity co-investors

Trendlines teams up with Ozi Amanat as Startup SG Equity co-investors

By: 
Michelle Zhu
08/02/18, 05:36 pm

SINGAPORE (Feb 8): Trendlines Medical Singapore, a subsidiary of Israeli company The Trendlines Group, is partnering Singapore-based investor Ozi Amanat’s venture capital firm, K2 Global, to collaborate in SPRING SEEDS Capital’s (SSC) $100 million investment allocation via the Startup SG Equity scheme.

Under the Startup SG Equity scheme, SSC supports early-stage startups across the technology and industry domain areas, and catalyses private-sector investments for startups via government equity co-investment.

The scheme announced its $100 million investment allocation in July 2017 to groom start-ups, and issued a call to its appointed partners to co-invest in the health & biomedical sciences and other fields.

In a Thursday announcement, Trendlines says it intends to invest in medical technology companies seeking Series A funding through its partnership with K2 Global. Both companies anticipate co-investing with SCC in more than 11 companies over the agreed partnership period of eight years.

They also consider the pipeline of deals originating from Trendlines Medical Singapore’s incubator, along with other companies that have strong development focus in Singapore, as “a rich environment for investment”.

Eric Loh, CEO of Trendlines Medical Singapore, sees the collaboration as one that leverages Trendlines’ experience and track record in identifying, incubating and grooming medical technology companies, while working closely with K2 Global to provide growth capital and support to help scale operations and facilitate global opportunities.

“This is an ideal relationship that will contribute substantial value to Singapore’s medical technology start-up ecosystem,” says Loh.

“Our participation in the Startup SG Equity program broadens our ability to develop early-stage medical technology companies in Singapore. Our collaboration with K2 Global will further strengthen our successful efforts in raising funds from strategic investors to boost the value of our portfolio companies. We expect numerous successful investment outcomes in the coming years,” adds Todd Dollinger, chairman of Trendlines Medical Singapore.

Shares in Trendlines close flat at 14 cents on Thursday. 

Soildbuild REIT posts 4.9% increase in 4Q DPU to 1.451 cents

SINGAPORE (Jan 21): The manager of Soilbuild Business Space REIT (Soilbuild REIT) has declared distribution per unit (DPU) of 1.451 cents for the 4Q18 ended December, some 4.9% higher than DPU of 1.383 cents a year ago. This brings total DPU for FY18 to 5.284 cents, some 7.5% lower than total DPU of 5.712 cents a year ago. Gross revenue grew 24.3% to $25.8 million in 4Q18, from $20.7 million a year ago. This was mainly due to the liquidation proceeds received from Technics Offshore Engineering, conversion of Solaris into a multi-tenanted property, and the maiden contribution from two ....
Read More >>

ST Engineering's electronics arm secures $351 mil contract wins in 4Q18

SINGAPORE (Jan 21): ST Engineering announced that its electronics arm has secured $351 million worth of contracts in 4Q18, bringing the total amount of contract wins in 2018 to $2.19 billion. These contracts were for its solutions in mobility, satellite communications, Internet of Things (IoT), and cybersecurity, as well as defence. The group secured contracts to supply a Passenger Information System for Shanghai Metro Line 14, and Platform Screen Doors for Bangkok’s MRT line. In Singapore, contracts were secured to supply communications systems for Circle Line Stage 6 and Thomson L....
Read More >>

DBS kept at 'buy' with still more upside expected ahead: RHB

SINGAPORE (Jan 21): RHB Research is maintaining its “buy” call on DBS Group Holdings with an unchanged target price of $29.80. This comes on the back of expectations of still more upside ahead, led by widening net interest margin (NIM). Analyst Leng Seng Choon notes that the 3-month SIBOR has been on a rising trend. It currently stands at 1.89%, after hitting an average of 1.73% in 4Q18 – some 0.1 percentage point higher than the preceding quarter. While he explains that there is some lag effect from the SIBOR rise to filter through to NIM widening, Leng believes DBS’ 4Q18 NIM....
Read More >>